Market Snapshot
S&P Futures
3,779.5
Dow Futures
30,569
Nasdaq Futures
11,622.75
AVROBIO, Inc. (AVRO) stock rallied over 1.98% intraday to trade at $0.94 a share on NASDAQ. The stock opened with a gain of 2.17% at $0.928 and touched an intraday high of $0.97, rising 2.17% against the last close of $0.92. The stock went to a low of $0.92 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-05 | $0.928 | $0.97 | $0.92 | $0.938 | 176,593 |
2022-07-01 | $0.92 | $0.97 | $0.91 | $0.92 | 228,700 |
2022-06-30 | $0.98 | $1 | $0.92 | $0.92 | 309,200 |
2022-06-29 | $0.99 | $1.02 | $0.96 | $1.01 | 474,100 |
2022-06-28 | $1.02 | $1.03 | $0.95 | $0.96 | 462,800 |
2022-06-27 | $1 | $1.02 | $0.96 | $1 | 118,300 |
2022-06-24 | $1 | $1.03 | $0.95 | $0.98 | 4,657,700 |
2022-06-23 | $0.96 | $1.02 | $0.94 | $1.01 | 537,300 |
2022-06-22 | $0.94 | $1 | $0.92 | $0.95 | 485,700 |
2022-06-21 | $0.95 | $0.97 | $0.92 | $0.94 | 235,100 |
Employees-
Beta1.61
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO, Inc. (NASDAQ: AVRO) stock price is $0.94 as of the last check on Tuesday, July 5. During the trading session, AVRO stock reached the peak price of $0.97 while $0.92 was the lowest point it dropped to.
The NASDAQ listed AVRO is part of Biotechnology industry that operates in the broader Health Care sector. AVROBIO, Inc. , a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide.
Mr. Kim Raineri M.B.A.
Chief Manufacturing & Technology Officer
Ms. Georgette Verdin
Chief HR Officer
Mr. Geoff MacKay BSc
Co- Founder, Pres, CEO & Director
Mr. Erik John Ostrowski M.B.A.
CFO & Treasurer
AVRO stock traded closed the last session at $0.938, which is $0.02 or 1.98% lower than its previous close of $0.92. AVRO's current trading price is 26.80% lower than its 52-week high of $9.37 where as its distance from 52-week low of 0.74% is -89.99%.
Number of AVRO employees currently stands at -. AVRO operates from Building 300, Suite 201 One Kendall Square, Cambridge, MA 02139, United States.
Official Webiste of $AVRO is: https://www.avrobio.com
AVRO could be contacted at AVRO operates from Building 300, Suite 201 One Kendall Square, Cambridge, MA 02139, United States, or at phone #617 914 8420 and can also be accessed through its website.
AVRO stock volume for the day was 201,584 shares while in the previous session number of AVRO shares traded was 176,593 . The average number of AVRO shares traded daily for last 3 months was 506.41 Thousands.
The percentage change in AVRO stock occurred in the recent session was 1.98% while the dollar amount for the price change in AVRO stock was $0.02.
In the recent session, the day high for AVRO stock was $0.97 while the low for AVRO stock touched on the day was $0.92.
The market value of AVRO currently stands at 41 Million with its latest stock price at $0.94 and 43.7 Million of its shares outstanding.